Molecular Targets and Cancer Therapeutics: Program

Educational Session 1: Cancer Genomics

3:00 p.m.-4:30 p.m.
Session Co-Chairpersons: Matthew L. Meyerson, Dana-Farber Cancer Institute, Boston, MA, USA and P. Andrew Futreal, University of Texas MD Anderson Cancer Center, Houston, TX, USA

Title to be announced
Matthew L. Meyerson

Challenges and opportunities for genomic medicine
P. Andrew Futreal

Title to be announced
Gad Getz, Broad Institute of MIT and Harvard, Cambridge, MA, USA

Break

4:30 p.m.-4:45 p.m.

Educational Session 2: PI3K and MEK Pathway Inhibitors

4:45 p.m.-6:15 p.m.
Session Co-Chairpersons: Lewis C. Cantley, Weill Cornell Medical College of Cornell University, New York, NY, and Richard M. Marais, Paterson Institute for Cancer Research, University of Manchester, Manchester, England

BRAF and RAS signalling in melanoma: From basic biology to clinical exploitation
Richard M. Marais

Title to be announced
Neal Rosen, Memorial Sloan-Kettering Cancer Center, New York, NY, USA

Title to be announced
Joan S. Brugge, Harvard Medical School, Boston, MA, USA

Networking Reception

6:30 p.m.-8:00 p.m.

Welcome and Opening Remarks

8:00 a.m.-8:05 a.m.

Jeffrey A. Engelman, Massachusetts General Hospital, Charlestown, MA, USA
Lee J. Helman, National Cancer Institute, Bethesda, MD, USA
Sabine Tejpar, Catholic University of Leuven, Leuven, Belgium

Keynote Lectures

8:05 a.m.-10:05 a.m.
Session Chairperson: Jeffrey A. Engelman, Massachusetts General Hospital, Charlestown, MA, USA

Wnt signaling, Lgr5 stem cells, and cancer
Hans Clevers, Hubrecht Institute, Utrecht, The Netherlands

Targeting the PD-1 pathway: Resetting the balance between the immune system and cancer
Suzanne L. Topalian, Johns Hopkins University School of Medicine, Kimmel Cancer Center, Baltimore, MD, USA

Break

10:05 a.m.-10:30 a.m.

Plenary Session 1: Latest Advances to Overcome Resistance to Targeted Therapies

10:30 a.m.-12:30 p.m.
Session Co-Chairpersons: René Bernards, Netherlands Cancer Institute, Amsterdam, The Netherlands, and Alice T. Shaw, Massachusetts General Hospital Cancer Center, Boston, MA, USA

Title to be announced
René Bernards

Mechanisms of resistance to RAF/MEK inhibitors
David B. Solit, Memorial Sloan-Kettering Cancer Center, New York, NY, USA

Title to be announced
William Pao, Vanderbilt University, Nashville, TN, USA

Title to be announced
Alice T. Shaw

Poster Session A / Exhibit Show

12:30 p.m.-3:00 p.m.

Plenary Session 2: Targeting the Metabolic Basis of Cancer

3:15 p.m.-5:15 p.m.
Eyal Gottlieb, Beatson Institute for Cancer Research, Bearsden, Glasgow, Scotland, and Craig B. Thompson, Memorial Sloan-Kettering Cancer Center, New York, NY, USA

The metabolic phase of the cell cycle
Eyal Gottlieb

Targeting the genetic basis of kidney cancer
W. Marston Linehan, National Cancer Institute, Bethesda, MD, USA

Turning metabolic addiction into cancer therapy
Craig B. Thompson

Additional speaker to be announced

Proffered Paper Session 1

5:30 p.m.-6:30 p.m.

Poster Session A / Exhibit Show (continued)

6:30 p.m.-7:30 p.m.

Plenary Session 3: Epigenetic Regulators as Therapeutic Targets

8:00 a.m.-10:00 a.m.
Session Co-Chairpersons: Chas Bountra, University of Oxford, Headington, England and James E. Bradner, Dana-Farber Cancer Institute, Boston, MA, USA

Title to be announced
Chas Bountra

Additional speakers to be announced

Break

10:00 a.m.-10:30 a.m.

Plenary Session 4: Targeting KRAS Mutant Cancer

10:30 a.m.-12:30 p.m.
Session Co-Chairpersons: Julian Downward, Cancer Research UK, London, England and Kevan Shokat, University of California, San Francisco, CA, USA

Specific vulnerabilities of RAS mutant cancer cells
Karen Cichowski, Harvard Medical School / Brigham & Women's Hospital, Boston, MA, USA

Title to be announced
Pasi A. Jänne, Dana-Farber Cancer Institute, Boston, MA, USA

Direct targeting of mutant Ras proteins
Kevan Shokat

Synthetic lethal approaches to targeting Ras mutant cancers
Julian Downward

Poster Session B / Exhibit Show

12:30 p.m.-3:00 p.m.

Concurrent Sessions 1-4

3:15 p.m.-5:15 p.m.

• Concurrent Session 1: RNAi Therapeutics: Hype or Hope?

  Session Co-Chairpersons: Frank McCormick, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA and Judy Lieberman, Harvard Medical School, Boston, MA, USA

  Opportunities for systemic treatment using siRNA in nanoparticles
  Frank McCormick

  Targeting TNBC and epithelial tumor initiating cells with aptamer-siRNA chimeras
  Judy Liebeman

  Prospects for miRNA and lncRNA based cancer therapeutics
  Reuven Agami, Netherlands Cancer Institute, Amsterdam, The Netherlands

  Additional speaker to be announced

• Concurrent Session 2: Molecular Diagnostics: Bringing the Latest Technologies to Clinical Development

  Session Co-Chairpersons: Anthony John Iafrate, Massachusetts General Hospital, Boston, MA, USA and Jean-Charles Soria, Institute Gustave-Roussy, Villejuif, France

  Concordance and divergence in driver mutations between primary and metastasis: Focus in NSCLC and colon cancer
  Jean-Charles Soria

  Additional speakers to be announced

• Concurrent Session 3: Novel Laboratory Models to Assess Cancer Therapeutics

  Session Co-Chairpersons: William R. Sellers, Novartis Institutes for BioMedical Research, Cambridge, MA,USA, and Norman E. Sharpless, Lineberger Comprehensive Cancer Center, UNC School of Medicine, Chapel Hill, NC, USA

  Drug testing in genetically engineered murine models
  Norman E. Sharpless

  Conditionally reprogrammed cells for personalized medicine
  Richard Schlegel, Georgetown University School of Medicine, Washington, DC, USA

  Towards robust and systematic translational systems for cancer therapeutic development
  William R. Sellers

  Additional speaker to be announced

• Concurrent Session 4: Targeting Apoptotic Regulators

  Session Co-Chairpersons and Speakers to be announced

Proffered Paper Session 2

5:30 p.m.-6:30 p.m.

Poster Session B / Exhibit Show (continued)

6:30 p.m.-7:30 p.m.

Plenary Session 5: Genomic Heterogeneity in Cancers: Implications for Responsiveness

8:00 a.m.-10:00 a.m.
Session Co-Chairpersons: Elaine Mardis, Washington University School of Medicine, Saint Louis, MO, USA and Kornelia Polyak, Dana-Farber Cancer Institute, Boston, MA, USA

Heterogeneity in DCIS and invasive breast cancers
Kornelia Polyak

Mathematical modeling of tumor heterogeneity
Franziska Michor, Dana-Farber Cancer Institute, Boston, MA

An evolutionary view of heterogeneity in glioblastoma
Simon Tavaré, Cancer Research UK Cambridge Institute, Cambridge, England

Title to be announced
Elaine Mardis

Break

10:00 a.m.-10:30 a.m.

Plenary Session 6: CTCs, Non-Invasive Monitoring of Cancers

10:30 a.m.-12:30 p.m.
Session Co-Chairpersons: Alberto Bardelli, IRCC - University of Turin, Medical School, Candiolo, Italy and Daniel A. Haber, Massachusetts General Hospital, Charlestown, MA, USA

Liquid biopsies to monitor response and resistance to targeted therapies
Alberto Bardelli

Cancer exomes in plasma to track clonal evolution and resistance
Carlos M. Caldas, Cancer Research UK Cambridge Research Institute, Cambridge, England

Detection of chromosomal alterations in the circulation of cancer patients with whole-genome sequencing
Mark Sausen, Personal Genome Diagnostics, Baltimore, MD, USA

Title to be announced
Daniel A. Haber

Poster Session C / Exhibit Show

12:30 p.m.-3:00 p.m.

Concurrent Sessions 5-8

3:15 p.m.-5:15 p.m.

• Concurrent Session 5: Back to the Future: Targeting Cell Cycle and DNA Repair

  Session Co-Chairpersons:Alan D’Andrea, Dana-Farber Cancer Institute, Boston, MA, USA and Yves G. Pommier, National Cancer Institute-CCR, Bethesda, MD, USA

  PARP inhibitors: Trapping of PARP and rational for combinations
  Yves Pommier

  Targeting the fanconi anemia/BRCA pathway
  Alan D. D'Andrea

  Additional speakers to be announced

• Concurrent Session 6: EMT, Cellular Plasticity, Cellular Differentiation, and Response to Therapies

  Session Co-Chairpersons: Jeffrey E. Settleman, Genentech, Inc., South San Francisco, CA, USA and Robert A. Weinberg, MIT Whitehead Institute for Biomedical Research, Cambridge, MA, USA

  Cancer stem cells and the EMT
  Robert A. Weinberg

  Breast cancer stem cells
  Jenny Chang, Dan L. Duncan Cancer Center, Baylor College of Medicine, Houston, TX, USA

  Cell plasticity promotes drug resistance and pathway redundancy
  John D. Haley, OSI Pharmaceuticals, Farmingdale, NY, USA

  Reversible tolerance to anti-cancer drugs
  Jeffrey E. Settleman

• Concurrent Session 7: Developing Combination Therapy Approaches in the Lab and Clinic

  Session Co-Chairpersons: Jeffrey A. Engelman, Massachusetts General Hospital, Charlestown, MA, USA, and José Baselga, Memorial Sloan-Kettering Cancer Center, New York, NY, USA

  Speakers to be announced

• Concurrent Session 8: Using Genomics from Cell Line Screens to Inform Drug Development

  Session Co-Chairpersons: Mathew Garnett, Wellcome Trust Sanger Institute, Hinxton, Cambridge, England and Levi A. Garraway, Dana-Farber Cancer Institute, Boston, MA, USA

  Speakers to be announced

Proffered Paper Session 3

5:30 p.m.-6:30 p.m.

Poster Session C / Exhibit Show (continued)

6:30 p.m.-7:30 p.m.

Plenary Session 7: Immunotherapy

8:00 a.m.-10:00 a.m.
Session Co-Chairpersons: Alexander M. Marie Eggermont, Institut Gustave Roussy, Paris, France, and Carl H. June, Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA, USA

Speakers to be announced

Break

10:00 a.m.-10:30 a.m.

Plenary Session 8: Policy topic to be announced

10:30 a.m.-12:30 p.m.

Closing Remarks / Departure

12:30 p.m.-12:45 p.m.